Navigation Links
KaloBios Provides Clinical Update and Reports Second Quarter Financial Results
Date:8/7/2014

ct management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the potential timing and outcomes of clinical studies of KB001-A and KB004 undertaken now or in the future; the ability of the company to timely source adequate supply of its development products from third party manufacturers on whom the company depends; the potential, if any, for future development of KB003; the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that the company has initiated or plans to initiate; the company's ability to successfully progress, partner or complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 8, 2014, the Annual Report on Form 10-K filed on March 13, 2014, and the company's other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which s
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. KaloBios Provides Update on KB001-A Partnership and Clinical Status
2. KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
3. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
4. KaloBios Elects Laurie Smaldone Alsup, M.D. to Board
5. KaloBios to Present at Leerink Swann Rare Disease Roundtable
6. KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
7. Herb C. Cross to Join KaloBios as Chief Financial Officer
8. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
9. KaloBios to Present at Stifel Healthcare Conference 2013
10. KaloBios Reports First Quarter 2013 Financial Results
11. KaloBios to Present at Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... SOMERSET, N.J. , May 4, 2015 ... 20 percent seek help. During May – National Hearing ... hearing loss could be missing out on the sounds ... through the trees. To ensure that you ... sounds that color our world, Oticon, Inc. offers practical ...
(Date:5/4/2015)... -- Impax Laboratories, Inc. (NASDAQ: IPXL ) announced that ...  Donna M. Hughes, as Senior Vice President, Human Resources ... President, Chief Compliance Officer. Both Ms. Hughes and Ms. ... Officer, Fred Wilkinson . "We are ... team," said Fred Wilkinson , President and Chief ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:It's Better Hearing Month 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... ... at ADA 2008, ... today announced data showing that the use of mealtime,SYMLIN(R) (pramlintide acetate) ... achieving diabetes treatment goals of,improved glucose control without weight gain or ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... with AZ-002 (Staccato(R),alprazolam) in patients with panic disorder. ... which were the effect of AZ-002 on the ... of AZ-002 on the duration of a,doxapram-induced panic ...
Cached Medicine Technology:Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
(Date:5/4/2015)... May 04, 2015 The University ... today launched a new initiative at UC Davis ... generation of physicians committed to advancing Latino health. ... Medicos, or Preparing Students to Be Physicians, (“Prep ... will provide scholarships, mentorship and internship opportunities, a ...
(Date:5/4/2015)... New York, New York (PRWEB) May 04, 2015 ... as much as $2.4 billion to settle thousands of ... Type 2 diabetes medication increases the risk that a ... documents issued on April 28th, if 95% of those ... accord will resolve nearly 9,000 bladder cancer cases currently ...
(Date:5/4/2015)... May 04, 2015 McNeil & ... announces the expansion of coverage for its Emergency ... provider of industry-tailored insurance and proactive risk management to ... we are dedicated to providing our customers with unparalleled ... many evolving needs. We are excited to launch over ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a groundbreaking ceremony for ... Wednesday, April 22. , Johnson & Wales becomes the first ... re-alignment of Interstate-195. JWU’s new academic building, which will be ... Providence, is scheduled to be completed in July 2016. It ... purchased in 2012. , “It has long been our hope ...
(Date:5/4/2015)... 2015 TROY Healthcare Solutions is proud ... Regional User Group (RUG) Conference in Baltimore, MD from ... Regional User Group provides an opportunity for clients to ... exhibitor gallery. , In addition to sponsoring the event, ... North Atlantic RUG Conference. Attendees can stop by the ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3
... By Denise Mann HealthDay Reporter , MONDAY, ... up to 80 percent more likely to develop inflammatory bowel ... women without the uterine disorder, according to a new long-term ... lining -- the endometrium -- grows outside of the ...
... of cancer recurrence and cancer-related death in patients with esophageal ... Clinic found. Their 778-patient study, which appeared in the Dec. ... ( http://jco.ascopubs.org/ ), found that five-year survival in obese patients ... higher -- with esophageal cancer was 18 percent, compared to ...
... have been shown to have higher levels of education ... physically active, and have other characteristics that are associated ... been inconsistent in showing that, after adjustment for all ... of cardiovascular disease and mortality than do consumers of ...
... patterns of emergency care for an entire state has ... Indiana over a three-year period were by patients who ... conventional wisdom that patients are tightly bound to health ... The Regenstrief Institute study, "All Health Care Is ...
... "hypersensitive" they,re thought to be more fearful and feel ... Tel Aviv University shows that the anxious may not be ... sensitive enough. As part of a study on how ... Frenkel, a Ph.D. candidate in TAU,s School of Psychological Sciences ...
... Reporter , MONDAY, Dec. 19 (HealthDay News) -- Young women ... less time sunbathing or using tanning beds, two riskier behaviors, ... tanning product is a safe alternative to ultraviolet radiation (UV) ... the researchers said. They found that women who used tanning ...
Cached Medicine News:Health News:Endometriosis Tied to Higher Risk of Crohn's, Colitis 2Health News:Obesity linked to higher 5-year death rate after esophageal cancer surgery 2Health News:First study of emergency care for an entire state finds care isn't always local 2Health News:Are the anxious oblivious? 2Health News:Bottled Tan May Keep Women Out of the Sun 2Health News:Bottled Tan May Keep Women Out of the Sun 3
Sonogage introduces a new generation of A-Scan biometers for visual axis measurements and IOL calculations. The Eye-Scan™ employs the latest electronic and transducer technologies for unsurpass...
Improve your refractive outcome, with AXIS II precision biometry A-scan. Biometry clinically proven as accurate as partial coherence interferometry while not limited by dense media....
... measurement modes (Phakic, Aphakic, and IOL mode), ... length measuring mode. Normal phakic mode measures ... conversion at 1550m/s. The new Phakic 2 ... sonic velocity for conversion: anterior chamber and ...
... Combination A-Scan/Pachymeter with graphic display ... A-scans and A-Scan/Pachymeter combination units include ... Dioptimum and Binkhorst II formulas. Audible ... you get to visual axis. Constant ...
Medicine Products: